- Thinly traded nano cap Prana Biotechnology (PRAN +28%) is up on a healthy 49x surge in volume. Yesterday, it announced a research collaboration with Takeda Pharmaceuticals International (TKPYY +0.4%) to study the ability of PBT434 to slow or prevent neurodegeneration of the gastrointestinal system, characteristic of Parkinson's disease.
- The research will explore PBT434's effect on GI dysfunction, including constipation, lowered colon motility and inflammation.
- A recent paper published in Acta Neuropathologica Communications, suggested that PBT434 may reduce iron-mediated neurodegeneration and alpha-synuclein toxicity by reducing the formation of certain aggregates, freeing rescue neurons to restore motor function.